Low-dose tissue plasminogen activator thrombolysis in children

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 5, 2003, Pages 379-386

  Wang, Michael ^a   Hays, Taru ^a   Balasa, Vinod ^b   Bagatell, Rochelle ^c   Gruppo, Ralph ^b   Grabowski, Eric F ^d   Valentino, Leonard A ^e   Tsao Wu, George ^f   Manco Johnson, Marilyn J ^a,g  

^a CHILDREN S HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Rush Children's Hospital and Rush University Medical Center   (United States)

^f Alaska Center for Pediatrics   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Arterial and venous thrombosis; Post thrombotic syndrome; Thrombolysis in children; Tissue plasminogen activator

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; EXPERIENCE; FEMALE; HIGH RISK PATIENT; HUMAN; INFANT; MALE; NEWBORN; PATIENT SELECTION; PRIORITY JOURNAL; THROMBOSIS; VEIN BLOOD FLOW; VEIN THROMBOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0038559886     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200305000-00006     Document Type: Article

References (28)

1. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr Res 2000;47:763-6.
2. Bergmann SR, Fox KA, Ter-Pogossian MM, et al. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 1983;220:1181-3.
3. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase ¥¢rsus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet 1993;341:507.
4. TIMI Study Group. The Thrombolysis in Myocardial Infaction (TIMI) trial. Phase 1 findings. N Engl J Med 1985;312:932-6.
5. Comerota AJ. Thrombolytic therapy for acute deep vein thrombosis. In Comerota AJ, ed. Thrombolytic therapy for acute vascular disease. Philadelphia: JB Lippincott, 1995:175-95.
6. Manco-Johnson MJ, Nuss R, Hays T, et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000;136:425-6.
7. Gurgey A, Aslan D. Outcome of noncatheter-related thrombosis in children: influence of underlying or coexisting factors. J Pediatr Hematol Oncol 2001; 23:159-64.
8. Andrew M, Adams M, David M, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of Venous Thromboembolism. Blood 1994;83:1251-7.
9. Massicotte MP, Dix D, Monagle P, et al. on behalf of the Canadian Childhood Thrombophilia Program. Central venous catheter-related thrombosis in children: Analysis of the Canadian registry of venous thromboembolic complications. J Pediatr 1998;133:770-6.
10. Weiner GM, Castle V, DiPietro MA, et al. Successful treatment of neonatal arterial thrombi with recombinant tissue plasminogen activator. J Pediatr 1998; 133:133-6.
11. Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991;118: 467-72.
12. Dillon PW, Fox PS, Berg CJ, et al. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. J Pediatr Surg 1993; 28:1264-9.
13. Zenz W, Muntean W, Beitzke A, et al. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterization in infants and children. Br Heart J 1993;70:382-5.
14. Ries M, Singer H, Hofbeck M, Klinge J. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterization in infants and children [letter]. Br Heart J 1994;72:403.
15. Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1997;133: 137-40.
16. Knöfler R, Dinger J, Kabus M, et al. Thrombolytic therapy in children-clinical experiences with recombinant tissue-plasminogen activator. Semin Thromb Hemost 2001;27:169-74.
17. Asante-Korang A, Sreeram N, McKay R, Arnold R. Thrombolysis with tissue-type plasminogen activator following cardiac surgery in children. Int J Card 1992;35:317-22.
18. Nowak-Göttl U, Schwabe D, Schneider W, et al. Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy. Lancet 1992;340:1105.
19. Leaker M, Massicotte MP, Brooker L, et al. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996;76: 132-4.
20. Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of Thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001;139:682-8.
21. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119(1 Suppl):344S-70.
22. Giugliano RP, McCabe CH, Antman EM, et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001;141:742-50.
23. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001;119:108S-21.
24. Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg 2000;31:1307-12.
25. Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. J Vasc Interv Radiol 2000;11:411-20.
26. Chamuleau SA, de Winter RJ, Levi M, et al. Low-molecular-weight heparin as an adjunct to thrombolysis following acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group. Heart 1998;80:35-9.
27. Weitz JI, Hudoba M, Masel D, et al. Clot-bound thrombin is protected from inactivation by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385.
28. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93.